Richard Schilsky to Research Design
This is a "connection" page, showing publications Richard Schilsky has written about Research Design.
Connection Strength
1.644
-
Clinical trials in the era of personalized oncology. CA Cancer J Clin. 2011 Nov-Dec; 61(6):365-81.
Score: 0.314
-
The Targeted Agent and Profiling Utilization Registry Study: A pragmatic clinical trial. Clin Trials. 2023 Dec; 20(6):699-707.
Score: 0.177
-
Cooperative group tissue banks as research resources: the cancer and leukemia group B tissue repositories. Clin Cancer Res. 2002 May; 8(5):943-8.
Score: 0.163
-
Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement. Clin Cancer Res. 2021 05 01; 27(9):2394-2399.
Score: 0.149
-
Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement. J Immunother Cancer. 2018 10 19; 6(1):108.
Score: 0.127
-
Patient advocates' role in clinical trials: perspectives from Cancer and Leukemia Group B investigators and advocates. Cancer. 2012 Oct 01; 118(19):4801-5.
Score: 0.080
-
The next phase of chemoprevention research. Cancer Prev Res (Phila). 2011 Mar; 4(3):293-5.
Score: 0.075
-
American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites. J Clin Oncol. 2008 May 20; 26(15):2562-7.
Score: 0.061
-
Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials. J Clin Oncol. 2008 Mar 10; 26(8):1371-8.
Score: 0.061
-
Target practice: oncology drug development in the era of genomic medicine. Clin Trials. 2007; 4(2):163-6; discussion 173-7.
Score: 0.056
-
The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3612s-6s.
Score: 0.054
-
Are targeted therapies really targeted? Clin Adv Hematol Oncol. 2003 Dec; 1(12):722-3.
Score: 0.045
-
Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations. Clin Cancer Res. 2021 05 01; 27(9):2430-2434.
Score: 0.037
-
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group. Clin Cancer Res. 2021 05 01; 27(9):2408-2415.
Score: 0.037
-
American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care. J Clin Oncol. 2021 01 10; 39(2):155-169.
Score: 0.037
-
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. Nature. 2019 10; 574(7776):127-131.
Score: 0.034
-
Challenges and approaches to implementing master/basket trials in oncology. Blood Adv. 2019 07 23; 3(14):2237-2243.
Score: 0.034
-
The promise of Immuno-oncology: implications for defining the value of cancer treatment. J Immunother Cancer. 2019 05 17; 7(1):129.
Score: 0.033
-
Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst. 1993 Oct 20; 85(20):1637-43.
Score: 0.023
-
Biological, clinical, and psychosocial correlates at the interface of cancer and aging research. J Natl Cancer Inst. 2012 Apr 18; 104(8):581-9.
Score: 0.020
-
Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B. J Clin Oncol. 2006 Oct 01; 24(28):4553-7.
Score: 0.014
-
Colorectal adenomas: a prototype for the use of surrogate end points in the development of cancer prevention drugs. Clin Cancer Res. 2004 Jun 01; 10(11):3908-18.
Score: 0.012